What is the current market size and future outlook for the roxadustat market?
The Roxadustat market size has grown strongly in recent years. It will grow from $6.44 billion in 2024 to $6.92 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to regulatory approvals in major markets, strong clinical trial results, increasing prevalence of chronic kidney disease, growing awareness of anemia management, and government support for anemia treatments.
The Roxadustat market size is expected to see strong growth in the next few years. It will grow to $9.16 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to ongoing research for new indications, increasing healthcare expenditure, demand for non-injectable anemia treatments, expanding reimbursement policies, and rising geriatric population. Major trends in the forecast period include a shift towards oral anemia treatments, increasing competition from alternative therapies, expansion of licensing agreements, growing investment in hypoxia-inducible factor research, and a focus on patient-centric treatment approaches.
Get Your Free Sample of The Global Roxadustat Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp
How has the roxadustat market evolved, and what factors have shaped its growth?
The rising number of people with chronic kidney disease (CKD) is expected to propel the growth of the Roxadustat market going forward. Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to function properly, often leading to kidney failure if left untreated. The number of people affected by chronic kidney disease is rising globally due to factors such as aging populations, increasing rates of diabetes, hypertension, and unhealthy lifestyles. Roxadustat helps manage chronic kidney disease by stimulating the production of erythropoietin, which increases red blood cell production and helps address anemia commonly associated with the condition, thereby improving overall kidney function and quality of life for patients. For instance, in December 2024, according to a report published by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, the mortality rates for chronic kidney disease experienced a modest annual rise, increasing by 4.2% in 2021 and 6.2% in 2022. Therefore, the rising number of people with chronic kidney disease (CKD) is driving the growth of the Roxadustat market.
What are the major segments of the roxadustat market?
The roxadustat market covered in this report is segmented –
1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions
Subsegments:
1) By 20mg: Oral Tablets, Injectable Formulations
2) By 50mg: Oral Tablets, Injectable Formulations
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report
Which companies dominate the roxadustat market?
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.
How will evolving trends contribute to the growth of the roxadustat market?
Major companies operating in the Roxadustat market are opting for reimbursement under the high-tech drugs scheme to ensure broader patient access by reducing financial barriers, thereby accelerating market uptake and demonstrating the cost-effectiveness of their innovative therapies. The high-tech drugs scheme is a government-managed program primarily in Ireland that provides reimbursement for the dispensing of expensive, highly specialized medications typically prescribed in hospital settings. For instance, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical company announced that its EVRENZO (Roxadustat) has been granted reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the first in a new class of orally administered hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors licensed and reimbursed in Ireland. The results showed Roxadustat was effective in achieving and maintaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, regardless of dialysis status and prior ESA treatment.
What are the key regional dynamics of the roxadustat market, and which region leads in market share?
North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Roxadustat Market Report 2025 Offer?
The roxadustat market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, leading to increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without the need for exogenous erythropoiesis-stimulating agents. It is used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
